Equities

Protagenic Therapeutics Inc

Protagenic Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.50
  • Today's Change0.010 / 0.68%
  • Shares traded4.89k
  • 1 Year change-24.62%
  • Beta1.0677
Data delayed at least 15 minutes, as of May 17 2024 16:54 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
OPERATIONS
Net income(5)(3.56)(4.52)
Depreciation/depletion0.030.000
Non-Cash items1.381.021.86
Cash taxes paid, supplemental000
Cash interest paid, supplemental000
Changes in working capital(0.11)0.54(0.14)
Total cash from operations(3.7)(1.99)(2.8)
INVESTING
Capital expenditures(0.15)0.00--
Other investing and cash flow items, total4.931.60(9.91)
Total cash from investing4.781.60(9.91)
FINANCING
Financing cash flow items----0
Total cash dividends paid------
Issuance (retirement) of stock, net--013
Issuance (retirement) of debt, net--00
Total cash from financing--013
NET CHANGE IN CASH
Foreign exchange effects0.000.070.00
Net change in cash1.07(0.33)(0.13)
Net cash-begin balance/reserved for future use0.220.540.67
Net cash-end balance/reserved for future use1.290.220.54
SUPPLEMENTAL INCOME
Depreciation, supplemental0.030.000
Cash interest paid, supplemental000
Cash taxes paid, supplemental000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.